Global Venous Thromboembolism Therapeutics Market Trends and Analysis 2017-2021

Report : Global Venous Thromboembolism Therapeutics Market 2017-2021 is a new market research publication announced by Reportstack. 

Report Outline: The global VTE therapeutics market is expected to benefit from the growing incidence of VTE worldwide. According to the CDC, every year around 0.9 million individuals are affected by VTE in the US and 60,000 to 100,000 individuals in the US die of VTE. Further, the presence of high unmet medical needs is expected to fuel the market growth. For instance, according to the CDC approximately 50% of individuals with VTE will have long-term complications, and 33% of individuals will have a recurrence within ten years.

For detailed report with TOC, please click here ​Global Venous Thromboembolism Therapeutics Market 2017-2021

Market Growth: The global venous thromboembolism therapeutic market to grow at a CAGR of 6.40% during the period 2017-2021.

Key vendors • Bayer HealthCare
• BMS
• Boehringer Ingelheim
• Daiichi Sankyo
• Johnson & Johnson
• Sanofi

Other prominent vendors • Altor Bioscience
• Armetheon
• Aspen Pharma
• BioInvent International
• eXIthera Pharmaceuticals
• Gamma Therapeutics
• GlycoMimetics
• Green Cross
• Isis Pharmaceutical
• Leo Pharma
• Pfizer
• Portola Pharmaceuticals
• ThromboGenics

Regions Covered: 

• Americas
• APAC
• EMEA

Companies Mentioned

Bayer HealthCare, BMS, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Sanofi, Altor Bioscience, Armetheon, Aspen Pharma, BioInvent International, eXIthera Pharmaceuticals, Gamma Therapeutics, GlycoMimetics, Green Cross, Isis Pharmaceutical, Leo Pharma, Pfizer, Portola Pharmaceuticals, ThromboGenics.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###